# Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use

> **NCT01204866** · PHASE1 · COMPLETED · sponsor: **PharmAthene, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Allergic Reactions

## Interventions

- **BIOLOGICAL:** Valortim and selected Components
- **DRUG:** Valortim and Selected Components

## Key facts

- **NCT ID:** NCT01204866
- **Lead sponsor:** PharmAthene, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2010-08
- **Final completion:** 2010-09
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2010-09-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01204866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01204866, "Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01204866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*